Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases

Key Points

  • Nucleoside and nucleotide analogues are largely used in the treatment of cancer and viral infections.

  • A large number of novel compounds continue to be synthesized and evaluated both by academia and the pharmaceutical industry, which underlines the important interest in this family of drugs.

  • Different strategies are being used to develop new agents, such as pronucleotides and conjugates.

  • New agents are expected to have different resistance profiles compared to already approved agents.

  • New interferon-free regimens to cure hepatitis C virus infection are likely to contain a potent and pan-genotypic active nucleoside or nucleotide analogue. Two of these — sofosbuvir and mericitabine — are in Phase III clinical trials.

Abstract

Nucleoside analogues have been in clinical use for almost 50 years and have become cornerstones of treatment for patients with cancer or viral infections. The approval of several additional drugs over the past decade demonstrates that this family still possesses strong potential. Here, we review new nucleoside analogues and associated compounds that are currently in preclinical or clinical development for the treatment of cancer and viral infections, and that aim to provide increased response rates and reduced side effects. We also highlight the different approaches used in the development of these drugs and the potential of personalized therapy.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: General structural and chemical modifications of nucleoside and nucleotide analogues.
Figure 2: Mechanism of action of nucleoside analogues.
Figure 3: Chemical structures of representative anticancer and antiviral nucleoside and nucleotide analogues in development.
Figure 4: The pronucleotide strategy.

References

  1. 1

    Elion, G. B. The quest for a cure. Annu. Rev. Pharmacol. Toxicol. 33, 1–23 (1993).

    CAS  Google Scholar 

  2. 2

    Elion, G. B. Acyclovir: discovery, mechanism of action, and selectivity. J. Med. Virol. Suppl. 1, 2–6 (1993).

    Google Scholar 

  3. 3

    De Clercq, E. A 40-year journey in search of selective antiviral chemotherapy. Annu. Rev. Pharmacol. Toxicol. 51, 1–24 (2011). This is a state-of-the-art review of the development of antiviral compounds, written by one of the pioneers in the field.

    CAS  Google Scholar 

  4. 4

    Holy, A. Antiviral acyclic nucleoside phosphonates structure activity studies. Antiviral Res. 71, 248–253 (2006).

    CAS  Google Scholar 

  5. 5

    De Clercq, E. & Holy, A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nature Rev. Drug Discov. 4, 928–940 (2005).

    CAS  Google Scholar 

  6. 6

    Cano-Soldado, P. & Pastor-Anglada, M. Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition. Med. Res. Rev. 32, 428–457 (2011).

    Google Scholar 

  7. 7

    Minuesa, G. et al. Drug uptake transporters in antiretroviral therapy. Pharmacol. Ther. 132, 268–279 (2011).

    CAS  Google Scholar 

  8. 8

    Roizman, B. & Knipe, D. M. in Fundamental Virology (eds Knipe, D. M. & Howley, P. M.) 1123–1184 (Lippincott William and Wilkins, 2001).

    Google Scholar 

  9. 9

    Andrei, G. et al. In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs. J. Virol. 86, 2641–2652 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. 10

    McGuigan, C. et al. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J. Antimicrob. Chemother. 60, 1316–1330 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  11. 11

    Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399–401 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 12

    Jordheim, L. P. & Dumontet, C. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim. Biophys. Acta 1776, 138–159 (2007).

    CAS  Google Scholar 

  13. 13

    Jordheim, L. P., Seve, P., Tredan, O. & Dumontet, C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 12, 693–702 (2011).

    CAS  Google Scholar 

  14. 14

    Marechal, R. et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143, 664–674 (2012).

    CAS  Google Scholar 

  15. 15

    Spratlin, J. et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 10, 6956–6961 (2004).

    CAS  Google Scholar 

  16. 16

    Yue, L. et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13, 29–38 (2003).

    CAS  Google Scholar 

  17. 17

    Ciccolini, J., Mercier, C., Dahan, L. & André, N. Integrating pharmacogenetics into gemcitabine dosing — time for a change? Nature Rev. Clin. Oncol. 8, 439–444 (2011). This article assesses cytidine deaminase activity in patients receiving gemcitabine.

    CAS  Google Scholar 

  18. 18

    Ciccolini, J. et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J. Clin. Oncol. 28, 160–165 (2010).

    CAS  Google Scholar 

  19. 19

    Rosell, R. et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin. Cancer Res. 10, 4215s–4219s (2004).

    CAS  Google Scholar 

  20. 20

    Marechal, R. et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res. 15, 2913–2919 (2009).

    CAS  Google Scholar 

  21. 21

    Geutjes, E. J., Tian, S., Roepman, P. & Bernards, R. Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs. Breast Cancer Res. Treat. 131, 809–818 (2012).

    CAS  Google Scholar 

  22. 22

    Marechal, R. et al. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 116, 5200–5206 (2010).

    CAS  Google Scholar 

  23. 23

    Galmarini, C. M. et al. Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 98, 1922–1926 (2001).

    CAS  Google Scholar 

  24. 24

    Suzuki, K. et al. Clinical significance of high-Km 5′-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome. Leuk. Res. 31, 1343–1349 (2007).

    CAS  Google Scholar 

  25. 25

    Robins, M. J. et al. Improved syntheses of 5′-S-(2-aminoethyl)-6-N-(4-nitrobenzyl)-5′-thioadenosine (SAENTA), analogues, and fluorescent probe conjugates: analysis of cell-surface human equilibrative nucleoside transporter 1 (hENT1) levels for prediction of the antitumor efficacy of gemcitabine. J. Med. Chem. 53, 6040–6053 (2010).

    CAS  Google Scholar 

  26. 26

    Tang, M. W., Liu, T. F. & Shafer, R. W. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology 55, 98–101 (2012).

    Google Scholar 

  27. 27

    Tang, M. W. & Shafer, R. W. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 72, e1–e25 (2012).

    PubMed  PubMed Central  Google Scholar 

  28. 28

    Zoulim, F. & Locarnini, S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137, 1593–1608 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29

    Bushman, F. D. et al. Massively parallel pyrosequencing in HIV research. AIDS 22, 1411–1415 (2008).

    PubMed  PubMed Central  Google Scholar 

  30. 30

    Newman, R. M. et al. Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants. J Infect. Dis. 6 Nov 2012 (doi:10.1093/infdis/jis679).

    PubMed  PubMed Central  Google Scholar 

  31. 31

    Solmone, M. et al. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J. Virol. 83, 1718–1726 (2009).

    CAS  Google Scholar 

  32. 32

    Ford, L. T. & Berg, J. D. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J. Clin. Pathol. 63, 288–295 (2010).

    CAS  Google Scholar 

  33. 33

    Adam de Beaumais, T. & Jacqz-Aigrain, E. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur. J. Clin. Pharmacol. 68, 1233–1242 (2012).

    CAS  Google Scholar 

  34. 34

    Eichelbaum, M., Ingelman-Sundberg, M. & Evans, W. E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119–137 (2006).

    CAS  Google Scholar 

  35. 35

    Kantarjian, H. et al. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 13, 1096–1104 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36

    Krett, N. L. et al. 8-amino-adenosine is a potential therapeutic agent for multiple myeloma. Mol. Cancer Ther. 3, 1411–1420 (2004).

    CAS  Google Scholar 

  37. 37

    Gandhi, V. et al. 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res. 61, 5474–5479 (2001). This study shows the multiple and uncommon mechanisms of action of 8-chloro-adenosine; this compound acts as an analogue of ATP and is not incorporated into DNA.

    CAS  Google Scholar 

  38. 38

    Frey, J. A. & Gandhi, V. 8-amino-adenosine inhibits multiple mechanisms of transcription. Mol. Cancer Ther. 9, 236–245 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  39. 39

    Stellrecht, C. M., Ayres, M., Arya, R. & Gandhi, V. A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels. Breast Cancer Res. Treat. 121, 355–364 (2010).

    CAS  Google Scholar 

  40. 40

    Stellrecht, C. M., Phillip, C. J., Cervantes-Gomez, F. & Gandhi, V. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res. 67, 9913–9920 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  41. 41

    Yang, S. Y. et al. Inhibition of topoisomerase II by 8-chloro-adenosine triphosphate induces DNA double-stranded breaks in 8-chloro-adenosine-exposed human myelocytic leukemia K562 cells. Biochem. Pharmacol. 77, 433–443 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42

    Gu, Y. Y. et al. 8-chloro-adenosine inhibits growth at least partly by interfering with actin polymerization in cultured human lung cancer cells. Biochem. Pharmacol. 72, 541–550 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  43. 43

    Choi, W. J. et al. Fluorocyclopentenyl-cytosine with broad spectrum and potent antitumor activity. J. Med. Chem. 55, 4521–4525 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  44. 44

    Peters, G. J. et al. Metabolism and mechanism of action of fluorocyclopentenylcytosine (RX-3117). in: 103rd Annual Meeting of the American Association for Cancer Research (Chicago, Illinois, USA; 2012).

    Google Scholar 

  45. 45

    Tiwari, K. N. et al. Synthesis of 4′-thio-beta-D-arabinofuranosylcytosine (4′-thio-ara-C) and comparison of its anticancer activity with that of ara-C. Nucleosides Nucleotides Nucleic Acids 19, 329–340 (2000).

    CAS  PubMed  PubMed Central  Google Scholar 

  46. 46

    Lee, C. P. et al. A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies. Clin. Cancer Res. 12, 2841–2848 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  47. 47

    Waud, W. R., Gilbert, K. S., Shepherd, R. V., Montgomery, J. A. & Secrist, J. A. Preclinical antitumor activity of 4′-thio-beta-D-arabinofuranosylcytosine (4′-thio-ara-C). Cancer Chemother. Pharmacol. 51, 422–426 (2003).

    CAS  PubMed  PubMed Central  Google Scholar 

  48. 48

    Someya, H., Waud, W. R. & Parker, W. B. Long intracellular retention of 4′-thio-arabinofuranosylcytosine 5′-triphosphate as a critical factor for the anti-solid tumor activity of 4′-thio-arabinofuranosylcytosine. Cancer Chemother. Pharmacol. 57, 772–780 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  49. 49

    Stuyver, L. J. et al. Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2′-deoxy-2′-fluorocytidine. Antimicrob. Agents Chemother. 48, 651–654 (2004). This paper reports the importance of the fluoro group at the 2′ position of cytidine for improved antiviral activity and specificity, as viral polymerases seem to be more tolerant towards the incorporation of such a compound.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. 50

    Clark, J. L. et al. Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J. Med. Chem. 48, 5504–5508 (2005).

    CAS  PubMed  PubMed Central  Google Scholar 

  51. 51

    Pierra, C. et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J. Med. Chem. 49, 6614–6620 (2006). This study highlights the discovery of valopicitabine, which was the first nucleoside analogue to be evaluated for the treatment of patients with HCV infection.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. 52

    O'Brien, C. et al. Randomized trial of valopicitabine (NM283), alone or with peg-interferon, versus retreatment with peg-interferon plus ribavirin (pegifn/RBV) in hepatitis C patients with previous non-response to pegIFN/RBV: first interim results. Hepatology 42, 234A (2005).

    Google Scholar 

  53. 53

    Pockros, P. J. et al. JUMP-C: a randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients. Hepatology 28 Jan 2013 (doi:10.1002/hep.26275).

    CAS  PubMed  PubMed Central  Google Scholar 

  54. 54

    Wedemeyer, H. et al. PROPEL: a randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patients. Hepatology 24 Jan 2013 (doi:10.1002/hep.26274).

    CAS  PubMed  PubMed Central  Google Scholar 

  55. 55

    Le Pogam, S. et al. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J. Infect. Dis. 202, 1510–1519 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  56. 56

    Reddy, R. et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 46, 862A–863A (2007).

    Google Scholar 

  57. 57

    Chu, T. W. et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 142, 790–795 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  58. 58

    Gane, E. J. et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376, 1467–1475 (2010). This is one of the first reports to describe the combinational use of a nucleoside analogue in an interferon-free regimen in patients with HCV infection.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. 59

    DeJesus, E. et al. Elvucitabine versus lamivudine with tenofovir and efavirenz in ART-naïve HIV-1-infected patients: 96-week final results. in: 17th Conference on Retroviruses and Opportunistic Infections [online], (San Francisco, California, USA; 2010).

    Google Scholar 

  60. 60

    Bethell, R. C., Lie, Y. S. & Parkin, N. T. In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antivir. Chem. Chemother. 16, 295–302 (2005).

    CAS  Google Scholar 

  61. 61

    Gu, Z. et al. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50, 625–631 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  62. 62

    Cahn, P. & Wainberg, M. A. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine. J. Antimicrob. Chemother. 65, 213–217 (2010).

    CAS  Google Scholar 

  63. 63

    Nitanda, T. et al. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine in vitro. Antimicrob. Agents Chemother. 49, 3355–3360 (2005).

    CAS  PubMed  PubMed Central  Google Scholar 

  64. 64

    Wang, X., Tanaka, H., Baba, M. & Cheng, Y. C. Retention of metabolites of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cells. Antimicrob. Agents Chemother. 53, 3317–3324 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  65. 65

    De Clercq, E. Highlights in antiviral drug research: antivirals at the horizon. Med. Res. Rev. 2 May 2012 (10.1002/med.21256).

  66. 66

    Price, N. B. & Prichard, M. N. Progress in the development of new therapies for herpesvirus infections. Curr. Opin. Virol. 1, 548–554 (2011). This review presents new therapies for herpesvirus infection.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. 67

    Kern, E. R. et al. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob. Agents Chemother. 48, 4745–4753 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  68. 68

    Chou, S. & Bowlin, T. L. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob. Agents Chemother. 55, 382–384 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  69. 69

    Secrist, J. A., Tiwari, K. N., Riordan, J. M. & Montgomery, J. A. Synthesis and biological activity of 2′-deoxy-4′-thio pyrimidine nucleosides. J. Med. Chem. 34, 2361–2366 (1991).

    CAS  PubMed  PubMed Central  Google Scholar 

  70. 70

    Kumar, S. et al. DNA containing 4′-thio-2′-deoxycytidine inhibits methylation by HhaI methyltransferase. Nucleic Acids Res. 25, 2773–2783 (1997).

    CAS  PubMed  PubMed Central  Google Scholar 

  71. 71

    Thottassery, J. V., Tiwari, K., Westbrook, L., Secrist, J. A. & Parker, W. B. Novel 2′-deoxycytidine analogs as DNA demethylation agents. Abstract 2537 in: 102nd Annual Meeting of the American Association for Cancer Research (Orlando, Florida, USA; 2011).

    Google Scholar 

  72. 72

    Marquez, V. E. et al. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann. NY Acad. Sci. 1058, 246–254 (2005).

    CAS  Google Scholar 

  73. 73

    Cheng, J. C. et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl Cancer Inst. 95, 399–409 (2003).

    CAS  Google Scholar 

  74. 74

    Wagner, C. R., Iyer, V. V. & McIntee, E. J. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Med. Res. Rev. 20, 417–451 (2000).

    CAS  Google Scholar 

  75. 75

    Rosowsky, A., Kim, S. H., Ross, J. & Wick, M. M. Lipophilic 5′-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2′-anhydro-3′-O-acyl derivatives as potential prodrugs. J. Med. Chem. 25, 171–178 (1982).

    CAS  Google Scholar 

  76. 76

    Jordheim, L. P. et al. Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clin. Cancer Res. 10, 5614–5621 (2004).

    CAS  Google Scholar 

  77. 77

    Hantz, O. et al. The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo. Antiviral Res. 40, 179–187 (1999).

    CAS  Google Scholar 

  78. 78

    Meier, C. & Balzarini, J. Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules. Antiviral Res. 71, 282–292 (2006).

    CAS  Google Scholar 

  79. 79

    Bontemps, F. et al. Study of the efficacy of a pronucleotide of 2-chloro-2′-deoxyadenosine in deoxycytidine kinase-deficient lymphoma cells. Nucleosides Nucleotides Nucleic Acids 25, 997–1000 (2006).

    CAS  Google Scholar 

  80. 80

    Erion, M. D. et al. Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 126, 5154–5163 (2004). This study reports the feasibility of the 'HepDirect' approach with several nucleosides.

    CAS  Google Scholar 

  81. 81

    Erion, M. D. et al. Liver-targeted drug delivery using HepDirect prodrugs. J. Pharmacol. Exp. Ther. 312, 554–560 (2005).

    CAS  Google Scholar 

  82. 82

    Reddy, K. R. et al. Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. J. Med. Chem. 51, 666–676 (2008).

    CAS  Google Scholar 

  83. 83

    McGuigan, C. et al. A phosphoramidate ProTide (NUC-1031) and acquired and intrinsic resistance to gemcitabine. J. Clin. Oncol. Abstr. S29, 13540 (2011).

    Google Scholar 

  84. 84

    Vail, D. M. et al. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clin. Cancer Res. 15, 3503–3510 (2009).

    CAS  Google Scholar 

  85. 85

    Ben-Kasus, T., Ben-Zvi, Z., Marquez, V. E., Kelley, J. A. & Agbaria, R. Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem. Pharmacol. 70, 121–133 (2005).

    CAS  Google Scholar 

  86. 86

    Yoo, C. B. et al. Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2′-deoxyzebularine. J. Med. Chem. 51, 7593–7601 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  87. 87

    Lam, A. M. et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 56, 3359–3368 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  88. 88

    Lalezari, J. et al. Once daily PSI-7977 plus PEGIFN/RBV in a phase 2b trial: rapid virologic suppression in treatment-naive patients with HCV GT2/GT3. J. Hepatol. 54, S28 (2011).

    Google Scholar 

  89. 89

    Gane, E. J. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34–44 (2013).

    CAS  Google Scholar 

  90. 90

    Sulkowski, M. S. et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. in: 63rd Annual Meeting of the American Association for the Study of Liver Diseases (Boston, Massachusetts, USA; 2012).

    Google Scholar 

  91. 91

    Sulkowski, M. et al. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/− ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3. J. Hepatol. 56, S560 (2012). This was one of the first reports to describe the combinational use of a nucleoside analogue in an interferon-free regimen in patients with HCV infection.

    Google Scholar 

  92. 92

    Cretton-Scott, E. et al. In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication. J. Hepatol. 48, S220 (2008).

    Google Scholar 

  93. 93

    Lalezari, J. et al. Antiviral activity, safety and pharmacokinetics of IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. Hepatology 50, 11A–12A (2009).

    Google Scholar 

  94. 94

    McCarville, J. F. et al. No resistance to IDX184 was detected in 3-day and 14-day clinical studies of IDX184 in genotype 1-infected HCV subjects. J. Hepatol. 54, S488–S489 (2011).

    Google Scholar 

  95. 95

    Chapman, H. et al. Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340. Nucleosides Nucleotides Nucleic Acids 20, 621–628 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  96. 96

    Babusis, D., Phan, T. K., Lee, W. A., Watkins, W. J. & Ray, A. S. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm (2012).

  97. 97

    Lee, W. A. et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob. Agents Chemother. 49, 1898–1906 (2005).

    CAS  PubMed  PubMed Central  Google Scholar 

  98. 98

    Ruane, P. et al. GS-7340 25 mg and 40 mg demonstrate superior efficacy to tenofovir 300 mg in a 10-day monotherapy study of HIV-1+ patients. Abstract 103 in: 19th Conference on Retroviruses and Opporunistic Infections [online], (Seattle, Washington, USA; 2012).

    Google Scholar 

  99. 99

    Uckun, F. M., Pendergrass, S., Venkatachalam, T. K., Qazi, S. & Richman, D. Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations. Antimicrob. Agents Chemother. 46, 3613–3616 (2002). This paper highlights the discovery of a compound that is active on multidrug-resistant HIV strains.

    CAS  PubMed  PubMed Central  Google Scholar 

  100. 100

    Cahn, P. et al. Preclinical and first-in-human Phase I clinical evaluation of stampidine, a potent anti-HIV pharmaceutical drug candidate. J. AIDS Clin. Res. 3, 138 (2012).

    Google Scholar 

  101. 101

    Uckun, F. M., Cahn, P., Qazi, S. & D'Cruz, O. Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS. Expert Opin. Investig. Drugs 21, 489–500 (2012).

    CAS  Google Scholar 

  102. 102

    Ryu, E. K. et al. Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5′-monophosphate-l-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-l-1,2-diacylglycerols. J. Med. Chem. 25, 1322–1329 (1982).

    CAS  Google Scholar 

  103. 103

    Aoshima, M., Tsukagoshi, S., Sakurai, Y., Oh-ishi, J. I. & Ishida, T. N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent. Cancer Res. 37, 2481–2486 (1977).

    CAS  PubMed  Google Scholar 

  104. 104

    Breistol, K. et al. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res. 59, 2944–2949 (1999).

    CAS  PubMed  Google Scholar 

  105. 105

    Adema, A. D. et al. Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Invest. New Drugs 30, 1908–1916 (2012).

    CAS  Google Scholar 

  106. 106

    Galmarini, C. M., Myhren, F. & Sandvold, M. L. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br. J. Haematol. 144, 273–275 (2009).

    Google Scholar 

  107. 107

    Immordino, M. L. et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J. Control Release 100, 331–346 (2004).

    CAS  Google Scholar 

  108. 108

    Brusa, P., Immordino, M. L., Rocco, F. & Cattel, L. Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. Anticancer Res. 27, 195–199 (2007).

    CAS  PubMed  Google Scholar 

  109. 109

    Chung, W. G., Sandoval, M. A., Sloat, B. R., Lansakara, P. D. & Cui, Z. Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1. J. Control Release 157, 132–140 (2012).

    CAS  Google Scholar 

  110. 110

    Bergman, A. M. et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem. Pharmacol. 67, 503–511 (2004).

    CAS  Google Scholar 

  111. 111

    Bergman, A. M. et al. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest. New Drugs 29, 456–466 (2011).

    CAS  Google Scholar 

  112. 112

    Damaraju, V. L. et al. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides Nucleotides Nucleic Acids 31, 236–255 (2012).

    CAS  Google Scholar 

  113. 113

    Garcia-Manteiga, J., Molina-Arcas, M., Casado, F. J., Mazo, A. & Pastor-Anglada, M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin. Cancer Res. 9, 5000–5008 (2003).

    CAS  Google Scholar 

  114. 114

    Couvreur, P. et al. Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small 4, 247–253 (2008).

    CAS  Google Scholar 

  115. 115

    Reddy, L. H. et al. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. Mol. Pharm. 6, 1526–1535 (2009). This study validates the in vitro feasibility of the squalenoylation approach.

    CAS  Google Scholar 

  116. 116

    Rejiba, S. et al. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine 7, 841–849 (2011).

    CAS  Google Scholar 

  117. 117

    Sarpietro, M. G. et al. Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. Int. J. Pharm. 406, 69–77 (2011).

    CAS  Google Scholar 

  118. 118

    Cosco, D. et al. Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases. Int. J. Nanomed. 7, 2535–2546 (2012).

    CAS  Google Scholar 

  119. 119

    Maksimenko, A. et al. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy. Cancer Lett. (2012).

  120. 120

    Kiew, L. V., Cheong, S. K., Sidik, K. & Chung, L. Y. Improved plasma stability and sustained release profile of gemcitabine via polypeptide conjugation. Int. J. Pharm. 391, 212–220 (2012).

    Google Scholar 

  121. 121

    Pasut, G. et al. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. J. Control Release 127, 239–248 (2008).

    CAS  Google Scholar 

  122. 122

    El-Mabhouh, A. A. & Mercer, J. R. 188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases. Eur. J. Nucl. Med. Mol. Imag. 35, 1240–1248 (2008).

    CAS  Google Scholar 

  123. 123

    El-Mabhouh, A. A. et al. A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases. Oncol. Res. 19, 287–295 (2011).

    CAS  Google Scholar 

  124. 124

    Guo, P. et al. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother. Pharmacol. 48, 169–176 (2001).

    CAS  Google Scholar 

  125. 125

    Strasser, S. et al. 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2. Differ. 74, 488–498 (2006).

    CAS  Google Scholar 

  126. 126

    Lanier, E. R. et al. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. Antimicrob. Agents Chemother. 54, 2901–2909 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  127. 127

    McGuigan, C. et al. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. J. Med. Chem. 42, 4479–4484 (1999).

    CAS  Google Scholar 

  128. 128

    Pentikis, H. S. et al. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob. Agents Chemother. 55, 2847–2854 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  129. 129

    Brueckner, B. et al. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Mol. Cancer Ther. 9, 1256–1264 (2010).

    CAS  Google Scholar 

  130. 130

    Veltkamp, S. A. et al. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin. Cancer Res. 14, 3477–3486 (2008).

    CAS  Google Scholar 

  131. 131

    Bender, D. M. et al. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J. Med. Chem. 52, 6958–6961 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  132. 132

    Pratt, S. E. et al. Human carboxylesterase 2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin. Cancer Res. 19, 1159–1168 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  133. 133

    Koolen, S. L. et al. Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin. Cancer Res. 17, 6071–6082 (2011). This is the first report of the clinical use of an orally active gemcitabine conjugate.

    CAS  PubMed  PubMed Central  Google Scholar 

  134. 134

    Hao, W. H. et al. In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation. Cancer Chemother. Pharmacol. 71, 379–388 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  135. 135

    Maloisel, F. et al. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase. Leukemia 16, 573–580 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  136. 136

    Mollee, P. et al. Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. Ann. Oncol. 15, 1810–1815 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  137. 137

    Horikoshi, A., Takei, K., Hosokawa, Y. & Sawada, S. The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients. Int. J. Hematol. 87, 118–125 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  138. 138

    Gokbuget, N. et al. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica 96, 238–244 (2011).

    PubMed  PubMed Central  Google Scholar 

  139. 139

    Calvagno, M. G. et al. Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes. Curr. Drug Deliv. 4, 89–101 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  140. 140

    Arias, J. L., Reddy, L. H. & Couvreur, P. Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system. Biomacromolecules 12, 97–104 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  141. 141

    Celia, C., Cosco, D., Paolino, D. & Fresta, M. Gemcitabine-loaded innovative nanocarriers versus GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. Expert Opin. Drug Deliv. 8, 1609–1629 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  142. 142

    Feldman, E. J. et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol. 29, 979–985 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  143. 143

    Zhao, X., Wu, J., Muthusamy, N., Byrd, J. C. & Lee, R. J. Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment. J. Pharm. Sci. 97, 1508–1518 (2008).

    CAS  Google Scholar 

  144. 144

    Rose, W. C., Crosswell, A. R., Bronson, J. J. & Martin, J. C. In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]-guanine and related phosphonate nucleotide analogues. J. Natl Cancer Inst. 82, 510–512 (1990).

    CAS  Google Scholar 

  145. 145

    Holy, A. et al. Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res. 13, 295–311 (1990).

    CAS  Google Scholar 

  146. 146

    Tsai, C. Y. et al. Targeting DNA repair in chronic lymphocytic leukemia cells with a novel acyclic nucleotide analogue, GS-9219. Clin. Cancer Res. 15, 3760–3769 (2009).

    CAS  Google Scholar 

  147. 147

    Suzuki, N., Nakagawa, F., Nukatsuka, M. & Fukushima, M. Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. Exp. Ther. Med. 2, 393–397 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  148. 148

    Temmink, O. H. et al. Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2. Mol. Cancer Ther. 9, 1047–1057 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  149. 149

    Emura, T., Murakami, Y., Nakagawa, F., Fukushima, M. & Kitazato, K. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int. J. Mol. Med. 13, 545–549 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  150. 150

    Yoshino, T. et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13, 993–1001 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  151. 151

    Clouser, C. L. et al. Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorg. Med. Chem. Lett. 22, 6642–6646 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  152. 152

    Clouser, C. L. et al. Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine. PLoS ONE 6, e15840 (2011). This study reports on the antiviral activity of the cytotoxic nucleoside analogue gemcitabine.

    CAS  PubMed  PubMed Central  Google Scholar 

  153. 153

    Elwell, L. P. et al. Antibacterial activity and mechanism of action of 3′-azido-3′-deoxythymidine (BW A509U). Antimicrob. Agents Chemother. 31, 274–280 (1987).

    CAS  PubMed  PubMed Central  Google Scholar 

  154. 154

    Lewin, C. S., Allen, R. A. & Amyes, S. G. Mechanisms of zidovudine resistance in bacteria. J. Med. Microbiol. 33, 235–238 (1990).

    CAS  PubMed  PubMed Central  Google Scholar 

  155. 155

    Doleans-Jordheim, A. et al. Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains. Eur. J. Clin. Microbiol. Infect. Dis. 30, 1249–1256 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  156. 156

    Jordheim, L. P. et al. Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin. Int. J. Antimicrob. Agents 39, 444–447 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  157. 157

    Groves, A. M., Win, T., Haim, S. B. & Ell, P. J. Non-[18F]FDG PET in clinical oncology. Lancet Oncol. 8, 822–830 (2007).

    PubMed  PubMed Central  Google Scholar 

  158. 158

    Giovannoni, G. et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362, 416–426 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  159. 159

    Tatlisumak, T. et al. Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke 29, 1952–1958 (1998).

    CAS  Google Scholar 

  160. 160

    Sharma, N. K., Mahadevan, N. & Balakumar, P. Adenosine transport blockade restores attenuated cardioprotective effects of adenosine preconditioning in the isolated diabetic rat heart: potential crosstalk with opioid receptors. Cardiovasc. Toxicol. 13, 22–32 (2013).

    CAS  Google Scholar 

  161. 161

    Richman, D. D. HIV chemotherapy. Nature 410, 995–1001 (2001).

    CAS  Google Scholar 

  162. 162

    Leyssen, P., De Clercq, E. & Neyts, J. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res. 78, 9–25 (2008).

    CAS  Google Scholar 

  163. 163

    Broder, C. C. Henipavirus outbreaks to antivirals: the current status of potential therapeutics. Curr. Opin. Virol. 2, 176–187 (2012).

    PubMed  PubMed Central  Google Scholar 

  164. 164

    Chevaliez, S., Brillet, R., Lazaro, E., Hezode, C. & Pawlotsky, J. M. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J. Virol. 81, 7732–7741 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  165. 165

    Vignuzzi, M., Stone, J. K. & Andino, R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 107, 173–181 (2005).

    CAS  PubMed  PubMed Central  Google Scholar 

  166. 166

    Ewald, B., Sampath, D. & Plunkett, W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 27, 6522–6537 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  167. 167

    McGinn, C. J., Shewach, D. S. & Lawrence, T. S. Radiosensitizing nucleosides. J. Natl Cancer Inst. 88, 1193–1203 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  168. 168

    Kantarjian, H. et al. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J. Clin. Oncol. 28, 285–291 (2010). This study shows the clinical safety of the new oral nucleoside analogue sapacitabine.

    CAS  PubMed  PubMed Central  Google Scholar 

  169. 169

    Gilbert, J., Carducci, M. A., Baker, S. D., Dees, E. C. & Donehower, R. A. Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies. Invest. New Drugs 24, 499–508 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  170. 170

    Delaunoit, T. et al. A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors. Invest. New Drugs 24, 327–333 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  171. 171

    Radhakrishnan, S. K. & Gartel, A. L. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res. 66, 3264–3270 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  172. 172

    Nekhai, S. et al. A novel anticancer agent ARC antagonizes HIV-1 and HCV. Oncogene 26, 3899–3903 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  173. 173

    Bhat, U. G. & Gartel, A. L. Nucleoside analog ARC targets Mcl-1 to induce apoptosis in leukemia cells. Leukemia 24, 851–855 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  174. 174

    Le Guerhier, F. et al. Antiviral activity of beta-l-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrob. Agents Chemother. 45, 1065–1077 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  175. 175

    Lin, T. S. et al. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-beta-l-cytidine (beta-l-d4C) and 2′,3′-dideoxy 2′,3′-didehydro-beta-l-5-fluorocytidine (beta-l-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J. Med. Chem. 39, 1757–1759 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  176. 176

    Le Guerhier, F. et al. Characterization of the antiviral effect of 2′,3′-dideoxy-2′, 3′-didehydro-beta-l-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob. Agents Chemother. 44, 111–122 (2000).

    CAS  PubMed  PubMed Central  Google Scholar 

  177. 177

    Cahn, P. et al. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. Aids 20, 1261–1268 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  178. 178

    Wainberg, M. A., Cahn, P., Bethell, R. C., Sawyer, J. & Cox, S. Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection. Antivir. Chem. Chemother. 18, 61–70 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  179. 179

    Gouy, M. H. et al. Special feature of mixed phosphotriester derivatives of cytarabine. Bioorg. Med. Chem. 17, 6340–6347 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  180. 180

    Tobias, S. C. & Borch, R. F. Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol. Pharm. 1, 112–116 (2004).

    CAS  Google Scholar 

  181. 181

    Rodriguez-Torres, M. et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol 58, 663–668 (2012).

    Google Scholar 

  182. 182

    Lawitz, E. et al. High rapid virologic response (RVR) with PSI-7977 qd plus PEG-IFN/RBV in a 28-day phase 2a trial. Hepatology 52, 706A (2010). This is a description of the antiviral activity of sofosbuvir, which is probably the first 'pure chain terminator' nucleotide analogue to be used against HCV.

    Google Scholar 

  183. 183

    Vernachio, J. H. et al. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2′-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob. Agents Chemother. 55, 1843–1851 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  184. 184

    O'Brien, S. et al. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. Br. J. Haematol. 158, 581–588 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  185. 185

    Giles, F. et al. Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. Leuk. Res. 36, e71–e73 (2012). This is a report on the clinical activity of the elaidic acid derivative of cytarabine.

    CAS  PubMed  PubMed Central  Google Scholar 

  186. 186

    Bildstein, L. et al. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. J. Control Release 147, 163–170 (2010).

    CAS  Google Scholar 

  187. 187

    Chuang, J. C. et al. S110, a 5-aza-2′-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol. Cancer Ther. 9, 1443–1450 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  188. 188

    Yoo, C. B. et al. Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 67, 6400–6408 (2007).

    CAS  Google Scholar 

  189. 189

    Painter, G. R. et al. Evaluation of hexadecyloxypropyl-9-R[2-(phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob. Agents Chemother. 51, 3505–3509 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  190. 190

    Painter, W. et al. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob. Agents Chemother. 56, 2726–2734 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the support of the Association pour la Recherche sur le Cancer (ARC) and the Ligue contre le Cancer. L.P.J. acknowledges the Olav Raagholt and Gerd Meidel Raagholt Foundation for Research (Olav Raagholt og Gerd Meidel Raagholts stiftelse for medisinsk forskning).

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Lars Petter Jordheim or David Durantel or Fabien Zoulim or Charles Dumontet.

Ethics declarations

Competing interests

F.Z. has received consulting/speaking fees from Gilead, Bristol-Myers Squibb and Janssen Cilag.

F.Z. and D.D. have received research grants from Roche.

C.D. and L.P.J. have received research grants from Clavis Pharma.

Related links

PowerPoint slides

Supplementary information

Supplementary information S1 (table)

Currently approved nucleos(t)ide analogues and indications (PDF 113 kb)

Supplementary information S2 (table)

Main enzymatic activities targeted by nucleos(t)ide analogues for different chronic viruses (PDF 118 kb)

Supplementary information S3 (table)

Mutations in different viral polymerases conferring resistance to nucleos(t)ide analogues (PDF 138 kb)

Supplementary information S4 (table)

Associations between genetic variants and response to nucleoside analogue therapy in cancer patients (PDF 147 kb)

Glossary

Ribonucleotide reductase

A complex intracellular enzyme that converts ribonucleoside diphosphates into deoxyribonucleoside diphosphates, and is targeted by anticancer agents such as gemcitabine.

Nucleobase

A nitrogen-containing heterocyclic compound that can be grouped into purines (adenine and guanine) and pyrimidines (cytosine, thymine and uracil).

Dose adaptation

Determination of the dose that should be administered to a patient based on predicted or observed toxicity.

Demethylating agents

Compounds that modify the methylation status of regulatory sequences in DNA, thereby modifying the levels of expression of the corresponding gene.

Nucleoside transporters

Membrane pumps that allow the uptake and/or the efflux of nucleosides by cells.

Chain elongation

The increase in length of DNA or RNA strands during replication or transcription.

Phenotypic assays

Assays in which biological function or cell response is measured as an index of drug action.

Pronucleotides

Phosphorylated nucleosides in which the phosphate is linked to a protective group to increase diffusion of the nucleoside across the cell membrane.

Nucleophilic attack

A chemical reaction in which a negatively charged entity forms a bond with a positively charged atom.

Prodrugs

Compounds that are administered as inactive pharmacological entities that are then metabolized in vivo into an active compound.

Sustained viral response

The absence of detectable virus in the blood for up to 6 months after treatment.

First-pass hepatic metabolism

The uptake and metabolism of an orally administered drug by enzymes in the liver, which reduces the concentration of the drug in the systemic circulation.

Phase 0 trial

A first-in-human clinical trial that is carried out to determine the pharmacodynamic and pharmacokinetic properties of a drug.

Drug repositioning

A strategy in which drugs that were initially developed in a given indication are subsequently applied to a novel indication.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jordheim, L., Durantel, D., Zoulim, F. et al. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov 12, 447–464 (2013). https://doi.org/10.1038/nrd4010

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing